Refractory Asthma
Conditions
Interventions
standard treatment group of asthma:Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation /Fluticasone Propionate Inhaled Aerosol/Budesonide and Formoterol Fumarate Powder for Inhalatio
treatment group of standard and Omalizumab for Injection for asthma:Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation /Fluticasone Propionate Inhaled Aerosol/Budesonide and Formot
treatment group of standard and Fecal Microbiota Transplantation for asthma:Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation /Fluticasone Propionate Inhaled Aerosol/Budesonide an
Sponsors
Department of Pediatrics, Xijing Hospital, The Air Force Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 14 Years
Inclusion criteria
Inclusion criteria: (1)Repeated wheezing, coughing, shortness of breath and chest tightness are mostly related to exposure to allergens, cold air, physical or chemical stimulation, respiratory tract infection, exercise and hyperventilation (such as laughter and crying), which often occur or worsen at night and/or in the morning. (2)During the attack, scattered or diffuse wheezing sounds can be heard in both lungs, mainly in the expiratory phase, and the expiratory phase is prolonged. (3)The above symptoms and signs were effectively or spontaneously relieved by anti asthma treatment. (4)Except wheezing, coughing, shortness of breath and chest tightness caused by other diseases. (5)Those with atypical clinical manifestations (such as no obvious wheezing or wheezing) should have at least one of the following: ? It is confirmed that there is reversible airflow restriction: a.Positive bronchodilation test: after 15 minutes of inhaled the quick results ß2 receptor agonists (such as salbutamol quantitative aerosol 200-400 µg), the Forced Expiratory Volume (FEV1) in the first second increased by = 12%; b.The pulmonary ventilation function improved after anti-inflammatory treatment: after 4 weeks of inhaled glucocorticoid and/or antileukotriene treatment, FEV1 increased by = 12%; ? Bronchial provocation test was positive; ? The mean value of maximum Peak Expiratory Flow (PEF) diurnal variation rate (continuous monitoring for 2 weeks) was = 13%. (6)Use includes inhalation of medium and high doses of glucocorticoids and long-term effects ß2 asthma that can not be well controlled after standard treatment of two or more kinds of agonists for at least 3-6 months. Those conforming to 1~4, 6 or 4-6 can be diagnosed as refractory asthma. The pulmonary ventilation function should be checked as far as possible to obtain the objective diagnostic basis of variable expiratory airflow restriction, avoid insufficient diagnosis or excessive diagnosis, and facilitate the long-term standardized control treatment of asthma.
Exclusion criteria
Exclusion criteria: (1)Aged over 14; (2)The children have fever, intestinal obstruction, intestinal bleeding, multiple organ failure, severe immunodeficiency disease and other diseases that may cause serious systemic reactions after Fecal Microbiota Transplantation; (3)Take antibiotics, non steroidal anti-inflammatory drugs(NSAIDs), microecological agents, gastric motility drugs, acid inhibitors and other drugs that affect intestinal flora 2 weeks before treatment; (4)Other moderate and severe respiratory diseases; (5)Accompanied with other serious diseases that may affect their survival (including serious infection, serious heart, kidney, respiratory, blood, endocrine, neuropsychiatric and other diseases) or combined with tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary function;Expiratory nitric oxide level;IL-4?IL-5?IL-10?IL-13?IL-17A?IFN-? and serum IgE;Number of eosinophils in blood;Composition, function and metabolites of intestinal and respiratory flora; | — |
Countries
China
Contacts
Public ContactXin Sun
the First Affiliated Hospital of the Air Force Medical University
Outcome results
None listed